31 August 2015 - ALK today announced that it has successfully completed the registration procedure for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in 11 European countries.
The HDM SLIT-tablet is indicated in adult patients (18-65 years) diagnosed by a clinical history and by a positive test for HDM sensitisation with at least one of the following conditions:
Jens Bager, President and CEO of ALK says: "The approval of our HDM SLIT-tablet represents a major landmark for ALK and is the result of 10 years of research and development work. For the first time, patients in Europe will now have access to an effective, well documented and home-based treatment for house dust mite allergy."
For more details, go to: http://www.alk-abello.com/Pages/CorpFrontPage.aspx